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Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous
tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of
streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there
are problems that include reliance on daily streptomycin injections and side effects such as
ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combina-
tions that make BU treatment safer and shorter would be welcome. Following on from
reports that avermectins have activity againstMycobacterium tuberculosis, we tested the
in-vitro efficacy of ivermectin and moxidectin onM. ulcerans. We observed minimum inhibi-
tory concentrations of 4–8 μg/ml and time-kill assays using wild type and bioluminescent
M. ulcerans showed a significant dose-dependent reduction inM. ulcerans viability over
8-weeks. A synergistic killing-effect with rifampicin was also observed. Avermectins are well
tolerated, widely available and inexpensive. Based on our in vitro findings we suggest that
avermectins should be further evaluated for the treatment of BU.
Author Summary
Neglected tropical diseases such as Buruli ulcer predominantly afflict the poorest popula-
tions in the world and reduce quality of life. Buruli ulcer is a necrotising infection that de-
stroys the skin and soft tissue, frequently presenting as nodules or open ulcers. Buruli
ulcer is treated with antibiotics and sometimes surgery. Unfortunately the antibiotic treat-
ment can have toxic side effects, such as hearing loss. Also, patients must either be hospi-
talized or report daily to a treatment centre to get their medicine as the treatment is
delivered by injection.
In laboratory experiments we tested the susceptibility ofMycobacterium ulcerans,
which causes Buruli ulcer, to avermectins. Avermectins are drugs that are used to treat
common parasite and worm infections, such as river blindness. These drugs are
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inexpensive, have few side effects and are widely available. Our findings show that two
avermectins called ivermectin and moxidectin inhibit the growth and also killMycobacte-
rium ulcerans strains from both Africa and Australia. If their efficacy and safety also can
be proven in animal and human studies, these drugs will provide an inexpensive addition
to the current treatment of Buruli ulcer.
Introduction
Buruli ulcer (BU) is a neglected tropical disease that presents as skin nodules, plaques or oede-
matous lesions that can progress to open ulcers [1]. BU is caused by infection withMycobacte-
rium ulcerans, a mycobacterium that is related to the causative agents of tuberculosis and
leprosy [2]. Most BU patients are children under the age of 15 [3]. The mode of transmission
of the disease is not well understood. Superstitious beliefs predominate in rural West Africa, re-
sulting in delayed treatment seeking and stigmatization of patients [4,5]. Mortality associated
with BU is low nevertheless morbidity is high. Extensive ulcers frequently lead to lifelong phys-
ical disability [6,7].
No vaccine is available against Buruli ulcer and management focuses on early case detection
and treatment with surgery and antibiotics [8]. Previously, Buruli ulcer was treated with surgi-
cal excision only, but since 2004, an 8-week course of rifampicin and streptomycin is the stan-
dard treatment [9–11].
In case patients report early with limited lesions, the 8-week course of rifampicin and strep-
tomycin delivers a good quality of life at long-term follow up [12]. However, the median time
to heal is still 18 to 30 weeks, depending on the size of the lesion [10].
Patients presenting late to health care facilities have a much poorer prognosis and many suf-
fer from functional limitations due to the disease [6,7].
There is also the issue that daily injections with streptomycin are impractical and can have
serious side effects, such as ototoxicity [13]. It has been shown that all-oral treatment with ri-
fampicin and a macrolide or quinolone results in high cure rates [14]. Shorter duration of anti-
biotic courses and more safe treatment regimes that reduce the time to healing are desirable for
Buruli ulcer.
Avermectins are macrolides that are used to treat helminth-infection (such as strongyloidia-
sis or onchocerciasis) and parasitic infection (scabies) in humans and in animals. These orally
administered drugs are well tolerated and available worldwide. Ivermectin is on the essential
drugs list of the World Health Organization. A recent report showed that avermectins, includ-
ing ivermectin, moxidectin and selamectin, inhibit the growth of differentM. tuberculosis
strains in-vitro at concentrations of 2 to 8 μg/ml [15]. Motivated by these findings, we tested if
avermectins also inhibit and killM. ulcerans.
Materials and Methods
Bacterial strains
Two differentM. ulcerans clinical isolates were used, JKD8049 isolated from a patient in Victo-
ria, Australia in 2004 and 1117–13, a 2013 clinical isolate from Benin. For time-kill assays (see
below),M. ulcerans JKD8049 containing a bioluminescent reporter plasmid pMV306 hsp16
+luxG13 [16] was employed. TheMycobacterium marinum ‘M’ strain was also used. Mycobac-
teria were grown at 30°C in 7H9 Middlebrook broth supplemented with OADC (Becton
Activity of Avermectins againstM. ulcerans
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Dickinson, Sparks, MD, USA).M. ulcerans JKD8049 harbouring pMV306 hsp16+luxG13 was
grown in the presence of 25 μg/ml kanamycin.
Minimum inhibitory concentration (MIC) testing
Bacteria in mid-exponential growth phase were used for MIC testing. They were prepared to
0.5 Macfarlane standard and diluted 1:5 in PBS. A 500 μl volume of this preparation was used
to inoculate duplicate BBL™Mycobacteria Growth Indicator Tubes (MGITs) supplemented
with 0.5 ml OADC (Becton Dickinson, Sparks, MD, USA) that contained doubling dilutions of
moxidectin, ivermectin or rifampicin (Sigma-Aldrich, St. Louis, MO, USA.). The tubes were in-
cubated at 30°C and assessed daily for fluorescence, with a long-wave UV-A lamp (Wood’s
lamp) for 21 days. The tube with the lowest drug-concentration displaying no growth after this
period was considered as containing the inhibitory concentration. Solvent only and rifampicin
0.1 μg/ml were used controls.
Time-kill assays
Ten millilitre aliquots of mid-exponential growth phaseM. ulcerans JKD8049 were transferred
in duplicate to sterile 25cm2 tissue culture flasks containing 0, 8 and 20 μg/ml ivermectin. The
aim was to obtain aM. ulcerans concentration of at least 10^6 CFU/ml in each flask. Each
week, 50 μl of culture was sampled from each flask to assess viable bacteria remaining by CFU
counting. Ten-fold dilutions of the sub-samples were prepared in PBS and a 3 μl aliquot of
each dilution was spot plated in quintuplicate onto Middlebrook 7H10 agar containing 10%
OADC. After 8 weeks of incubation at 30°C plates were examined for growth. The growth/no
growth scores of the five technical replicates were used to calculate the most probable number
estimate of CFU per ml. Data was analyzed using GraphPad Prism v5.0d.
Bioluminescent kill curves
Three to five replicates of 200 μl aliquots of bioluminescentM. ulcerans JKD8049 in mid-
exponential growth were transferred into a white 96-well plate and antibiotics were added. The
plate was placed into a FLUOstar Omega plate reader (BMG LABTECH GmBH, Ortenberg
Germany). Light emission was read every 300 s via the top optic with the gain set at 3600 and
plate temperature at 30°C. Before each reading, plates were shaken at 100 rpm for 10 s in dou-
ble orbital mode. The results were recorded using Omega v3.00 R2 and analyzed using Mars
v3.01 R2 and GraphPad Prism v5.0d.
Results
M. ulcerans growth is inhibited by avermectins
M. ulcerans JKD8049,M. ulcerans 1117–13 andM.marinum were grown in MGIT tubes in the
presence of increasing concentrations of the ivermectin and moxidectin. At three weeks, no
fluorescence was observed at 8 μg/ml of ivermectin forM. ulcerans JKD8049 and at 4 μg/ml for
M. ulcerans 1117–13 (Table 1). Moxidectin inhibited the growth ofM. ulcerans JKD8049 at
4 μg/ml. The MIC forM.marinum was 32 μg/ml for ivermectin and above 64 μg/ml for moxi-
dectin (Table 1). These data show thatM. ulcerans but notM.marinum is susceptible to aver-
mectins. Growth of all bacteria was observed in the control tubes containing only the solvent
and no growth was observed in the tubes containing 0.1 μl/ml rifampicin.
Activity of Avermectins againstM. ulcerans
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M. ulcerans killing by avermectins
Time-kill assays were then performed to assess if avermectins not only inhibitM. ulcerans
growth but also kill the bacterium. Based on the MIC results above, a low and high dose of iver-
mectin was tested andM. ulcerans JKD8049 was exposed to either 8 μg/ml or 20 μg/ml iver-
mectin for eight weeks. A dose-dependent killing effect was observed with no CFU detected
from week-4 onwards at 20 μg/ml and week-5 onwards for 8 μg/ml (Fig 1).
Bioluminescence is an ATP-dependent process and it is therefore an excellent dynamic re-
porter of cellular metabolic activity [17]. A time-kill experiment was thus performed using bio-
luminescentM. ulcerans. Although the time frame of this experiment was quite short
(21 hours), continuous monitoring over that period again showed a dose-dependent impact of
ivermectin on bacterial viability (Fig 2). The reduction in bioluminescence at 21 hours was
higher in ivermectin at all concentrations tested (8, 16 and 32 μg/ml) compared to the rifampi-
cin positive control (Fig 2). Interestingly, the greatest impact on bacterial viability was observed
in the presence of a combined dose of 8 μg/ml ivermectin and 0.1 μg/ml rifampicin (Fig 2).
Discussion
The current treatment regimen of 8-weeks streptomycin and rifampicin for Buruli ulcer is
highly effective but also problematic and promising alternative all-oral treatments are sought
[13,14]. Here we have shown that ivermectin and moxidectin were able to inhibit the growth of
differentM. ulcerans strains at 4–8 μg/ml. These findings are comparable to previous research
where MICs of 1–8 μg/ml againstM. tuberculosis with ivermectin, selamectin, moxidectin or
doramectin were reported [15].
M.marinum, despite its close relationship toM. ulcerans, showed low susceptibility to both
ivermectin and moxidectin. We speculate that this difference may be explained at least in part
by the abundance of intact transporters and efflux systems inM.marinum and a corresponding
scarcity of the equivalent systems inM. ulcerans [18,19].
The 8-week time-kill experiment (Fig 1) showed that ivermectin at concentrations of 8 μg/
ml and above has a likely bactericidal effect onM. ulcerans. Future experiments will test lower
drug concentrations and use higher starting doses of bacteria. The long doubling time ofM.
ulcerans (>48h) complicates laboratory-testing methods using traditional culture and colony
counting approaches. Here we used bioluminescence as a rapid read-out of cell viability and
found it a useful technique for examining these slow-growing mycobacteria (Fig 2). Given the
MIC findings (Table 1), we were surprised to observe in the bioluminescent time-kill experi-
ments that ivermectin performed better than rifampicin at their given MIC concentrations.
Further investigation of this difference is warranted, probably by conducting the experiments
over an extended time period and beyond the 21 hours we were able to achieve here. A
Table 1. Minimal inhibitory concentration (MIC) of avermectins compared with rifampicin.
MIC (μg/ml) 1
M. ulcerans JKD8049 M. ulcerans 1117–13 M. marinum M
Ivermectin 8 4 32
Moxidectin 4 nt2 >64
Rifampicin 0.1 0.1 0.1
1Minimum concentration to prevent MGIT ﬂuorescence at 21 days;
2 not tested
doi:10.1371/journal.pntd.0003549.t001
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combination of 0.1 μg/ml rifampicin and 8 μg/ml ivermectin showed a synergistic killing effect.
Clinically, rifampicin may however decrease the serum concentration of ivermectin by the in-
duction of P-glycoprotein/ABCB1 in humans [20]. The extent to which this might be the case
is not known and requires further testing.
In the context of avermectins to treatM. tuberculosis infections, it has been argued that MICs
of 1–8 μg/ml are not achievable in humans [21]. Avermectins are mostly administered in much
lower doses and in single-doses for the treatment of helminth infection. A maximum plasma con-
centration of 54.4 ng/ml was observed in healthy volunteers receiving 150 μg/kg ivermectin [22].
There are few public data on the safety of higher doses or prolonged courses of avermectins
in humans and it unclear at what doses and over what time avermectins would have to be given
to Buruli ulcer patients. We would argue that obtaining avermectin plasma concentrations at
concentrations that approach MICs derived from in vitro experiments might not be needed for
clinical efficacy. In our bioluminescent time-kill assay, 8 μg/ml ivermectin was superior to
0.1 μg/ml rifampicin. It may be that the treatment duration for BU can be reduced and that
complete eradication of the microbe is not needed. Interference with theM. ulceransmycolac-
tone toxin synthesis machinery at concentrations that are sub-inhibitory for growth might be
sufficient to permit host immunity to then clear the infection.
Conclusions
The avermectins ivermectin and moxidectin inhibited growth ofM. ulcerans at 4–8μg/ml and
showed dose-dependent killing in culture-based and bioluminescence assays. The avermectins
Fig 1. Time-kill assay showing the effect of ivermectin againstM. ulcerans over 8-weeks.M. ulcerans
was grown in 25cm2 culture flasks in the presence of 0, 8 and 20μg/ml ivermectin. Ethanol (solvent for
ivermectin) at the concentration in the IVM-20 dose was used in the no-drug control. Weekly, ten-fold
dilutions of each culture were plated onto 7H10 agar, using a 3-μl spot-dilution method, with five replicates
per dilution. The plates were examined for growth after incubation for 8-weeks at 30°C, and colony forming
units per ml calculated. The mean and range for duplicate biological experiments are shown.
doi:10.1371/journal.pntd.0003549.g001
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are inexpensive and already widely distributed in West Africa through their use to treat river
blindness. Thus, there may be a chance to repurpose a well-tolerated drug for the treatment of
mycobacterial infections, bypassing the long and expensive pipeline for discovery of new anti-
microbials. We suggest that avermectins should be further investigated for the treatment ofM.
ulcerans, possibly in combination with other antibiotics, such fluoroquinolones.
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